Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine as first-line treatment for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
MOH_2017-04-09_000160Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, oxaliplatin and capecitabine in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Bristol Myers Squibb. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2017-04-09_000160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-09_000160.